GHK-Cu and Rosuvastatin Interaction: Safety, Mechanisms, and Clinical Guidance

What GHK-Cu Is and How It Works

GHK-Cu (glycyl-L-histidyl-L-lysine copper(II)) is a naturally occurring tripeptide first isolated from human plasma in 1973 by Loren Pickart. Plasma concentrations decline from roughly 200 ng/mL at age 20 to approximately 80 ng/mL by age 60 1. The peptide binds copper(II) with high affinity and has demonstrated wound-healing, anti-inflammatory, and collagen-stimulating properties in preclinical models 2.

GHK-Cu is administered topically, subcutaneously, or via microneedling in dermatology and regenerative medicine contexts. As a tripeptide, it is rapidly cleaved by serum and tissue peptidases into its constituent amino acids (glycine, histidine, lysine) and free copper(II) ions 3. This degradation pathway is entirely distinct from the cytochrome P450 system, UDP-glucuronosyltransferases, and hepatic organic anion transporting polypeptides (OATPs) that govern statin pharmacokinetics.

GHK-Cu is currently available as a compounded peptide under FDA Section 503A and has not received FDA approval as a standalone drug. No formal drug interaction studies have been submitted to the FDA for this compound.

How Rosuvastatin Is Metabolized

Rosuvastatin (Crestor) is an HMG-CoA reductase inhibitor approved for hyperlipidemia, mixed dyslipidemia, and primary prevention of cardiovascular events. Its pharmacokinetic profile differs from most other statins in ways that are directly relevant to interaction assessment 4.

Hepatic uptake of rosuvastatin depends on OATP1B1 (SLCO1B1) and OATP1B3 (SLCO1B3) transporters. Per the FDA-approved prescribing information, rosuvastatin undergoes limited metabolism: approximately 10% is metabolized by CYP2C9, with no significant involvement of CYP3A4 5. The drug is also a substrate of the breast cancer resistance protein (BCRP/ABCG2) efflux transporter.

Drugs that inhibit OATP1B1, BCRP, or CYP2C9 can raise rosuvastatin plasma concentrations and increase myopathy risk. The FDA label lists cyclosporine, certain protease inhibitors, and gemfibrozil as clinically significant interactors 5. GHK-Cu, as a simple tripeptide, has shown no inhibitory activity toward any of these transporters or enzymes in available literature.

Why a Pharmacokinetic Interaction Is Unlikely

The core question: does GHK-Cu alter rosuvastatin's absorption, distribution, metabolism, or excretion? Available pharmacological data suggest it does not.

GHK-Cu does not interact with CYP450 enzymes. A 2018 review of copper peptide biology confirmed that GHK-Cu is catabolized exclusively by peptidases and does not undergo phase I or phase II hepatic metabolism 3. No in vitro studies have demonstrated GHK-Cu inhibition or induction of CYP2C9, CYP3A4, or any other CYP isoform.

Rosuvastatin's OATP1B1 dependence is the most likely site for drug interactions. Known OATP1B1 inhibitors include cyclosporine (which increases rosuvastatin AUC 7.1-fold) and lopinavir/ritonavir (which increases AUC approximately 2-fold) 6. These are complex organic molecules with structural features that allow transporter binding. A tripeptide of 403 Da molecular weight with rapid systemic clearance has no known mechanism to inhibit OATP-mediated uptake 7.

BCRP (ABCG2) transport represents another potential interaction site for rosuvastatin. BCRP inhibitors such as eltrombopag can raise rosuvastatin exposure 5. No data link GHK-Cu to BCRP modulation. The absence of interaction evidence across three independent pathways (CYP2C9, OATP1B1/1B3, BCRP) makes a pharmacokinetic interaction between these two compounds improbable.

Pharmacodynamic Considerations: Copper, Muscle, and the Liver

While pharmacokinetic overlap is minimal, pharmacodynamic effects warrant separate consideration.

Copper homeostasis. Each molecule of GHK-Cu delivers one copper(II) ion. At typical subcutaneous doses of 1-3 mg/day, the copper contribution is small relative to dietary intake (the recommended daily allowance is 0.9 mg elemental copper per the National Institutes of Health Office of Dietary Supplements) 8. Copper overload (Wilson disease phenocopy) requires sustained intake far exceeding this threshold, typically above 10 mg/day over extended periods 9.

Hepatic copper accumulation could theoretically compound statin-related hepatotoxicity. Rosuvastatin carries a label warning for liver enzyme elevations, though clinically significant hepatotoxicity is rare. The JUPITER trial (N=17,802) found ALT elevations above 3x the upper limit of normal in 0.3% of the rosuvastatin 20 mg group vs. 0.2% in placebo 10. In patients with normal ceruloplasmin and no history of copper metabolism disorders, GHK-Cu at standard doses is unlikely to produce additive liver stress 8.

Muscle safety. Statin-associated muscle symptoms (SAMS) affect 7-29% of patients depending on the definition used 11. GHK-Cu has not been associated with myotoxicity. A 2020 study demonstrated that GHK-Cu actually upregulates genes involved in tissue repair and reduces inflammatory markers including IL-6 and TNF-alpha in fibroblast models 2. This anti-inflammatory profile would not be expected to worsen statin myopathy. Still, the absence of co-administration data means this remains theoretical.

Monitoring Recommendations for the Combination

No published guidelines address GHK-Cu/statin co-administration specifically. The following monitoring framework draws from standard statin safety protocols and copper metabolism principles.

Baseline labs before starting GHK-Cu alongside rosuvastatin:

• Creatine kinase (CK) to establish a pre-treatment reference
• Hepatic panel (ALT, AST, total bilirubin)
• Serum copper and ceruloplasmin if planning GHK-Cu use beyond 8 weeks 8

Follow-up monitoring:

• Repeat hepatic panel at 4-6 weeks, consistent with the 2018 ACC/AHA cholesterol guideline recommendations for statin therapy 12
• CK measurement only if the patient develops muscle pain, tenderness, or weakness (routine CK screening is not recommended per the same guideline)
• Serum copper at 12 weeks for subcutaneous GHK-Cu users; discontinue or reduce dose if serum copper exceeds 150 mcg/dL 9

Symptom-based alerts:

• New-onset muscle pain, dark urine, or unexplained fatigue should prompt immediate CK and hepatic panel measurement
• Nausea, jaundice, or right-upper-quadrant pain could indicate hepatic copper accumulation or statin hepatotoxicity and warrants urgent evaluation

Topical GHK-Cu: A Different Risk Profile

Most dermatologic applications of GHK-Cu involve topical serums at concentrations of 0.01-1%. Systemic absorption from intact skin is minimal. A pharmacokinetic analysis of topical copper peptides estimated that percutaneous absorption yields plasma levels several orders of magnitude below those achieved by subcutaneous injection 13.

For patients using topical GHK-Cu products (creams, serums) alongside oral rosuvastatin, the interaction risk is negligible. No special monitoring beyond standard statin follow-up is warranted. The discussion above regarding copper load, hepatic effects, and muscle safety applies primarily to injectable or high-dose oral formulations.

What the FDA Label Says About Rosuvastatin Interactions

The current FDA prescribing information for rosuvastatin lists specific interaction categories 5:

• Contraindicated: cyclosporine (7.1x AUC increase)
• Dose-limited to 5 mg: gemfibrozil, certain protease inhibitors (atazanavir/ritonavir, lopinavir/ritonavir)
• Dose-limited to 10 mg: regorafenib, darolutamide
• Caution advised: fenofibrate, niacin, colchicine, warfarin

GHK-Cu does not appear in any FDA interaction database, including the FDA Adverse Event Reporting System (FAERS), in connection with rosuvastatin or any other statin 14. This absence reflects both the low probability of interaction and the limited regulatory oversight of compounded peptides.

GHK-Cu Interactions with Other Medications

Beyond rosuvastatin, GHK-Cu's interaction profile with common medications deserves brief mention for patients on polypharmacy regimens.

No CYP inhibition or induction has been documented for GHK-Cu with any drug class. The peptide's rapid degradation half-life (estimated at 10-30 minutes in serum) limits its window for systemic interaction 1. Theoretical concerns exist for copper-sensitive medications: penicillamine chelates copper and could neutralize GHK-Cu's effects, while zinc supplements compete with copper for intestinal absorption via metallothionein induction 15.

Patients taking both GHK-Cu and high-dose zinc (above 40 mg/day) should separate dosing by at least 2 hours and monitor serum copper, as zinc-induced copper deficiency is a documented clinical entity, producing sideroblastic anemia and neutropenia in reported cases 15.

Clinical Decision Framework

For prescribers evaluating whether to allow GHK-Cu use in a patient already on rosuvastatin, the risk-benefit assessment can be organized into three tiers:

Low-risk (proceed with standard monitoring): Topical GHK-Cu at any concentration alongside any rosuvastatin dose. No dose adjustment needed for either agent.

Moderate-risk (proceed with enhanced monitoring): Subcutaneous GHK-Cu at 1-3 mg/day alongside rosuvastatin 5-20 mg. Add baseline serum copper, ceruloplasmin, and hepatic panel. Recheck at 6 and 12 weeks.

Higher-risk (individualize): Subcutaneous GHK-Cu at doses exceeding 3 mg/day, rosuvastatin 40 mg, or patients with pre-existing hepatic impairment, Wilson disease carrier status, or active SAMS. These patients need individualized copper and liver monitoring with shorter follow-up intervals. The 2018 ACC/AHA guideline recommends against rosuvastatin 40 mg in Asian patients due to a 2-fold increase in systemic exposure, and adding exogenous copper load warrants similar caution 12.

Rosuvastatin dose adjustments are not required based on GHK-Cu co-administration alone, as no mechanism supports altered statin exposure from this peptide 5.